GENOMIC & BIOMARKER DATA
ROOT HEALTH includes molecular and biomarker testing data for major actionable and clinically relevant biomarkers in NSCLC. The table below preserves the testing modalities, patient coverage, and total test volumes summarized in the current ROOT HEALTH workbook.
Cohort definition:
38,154 patients with NSCLC, excluding stage 0, who received cancer-directed
treatment at Samsung Medical Center.
Data cutoff: September 18, 2026.
Genomic and Biomarker Data Available in ROOT HEALTH
Patient-level testing coverage and total number of tests performed.
| Biomarker | Testing Modalities | Patients Tested (N) | Patients Tested (%) | Tests Performed (N) |
|---|---|---|---|---|
| EGFR | NGS, PCR, PCR-based sequencing | 31,667 | 83.0% | 70,617 |
| ALK | NGS, IHC, FISH | 30,631 | 80.3% | 56,943 |
| PD-L1 | IHC | 22,557 | 59.1% | 61,365 |
| BRAF V600E | NGS, PCR, PCR-based sequencing | 4,784 | 12.5% | 5,547 |
| RAS | NGS, PCR, PCR-based sequencing | 9,107 | 23.9% | 15,149 |
| ROS1 | NGS, PCR, IHC, FISH | 8,477 | 22.2% | 10,239 |
| NTRK | NGS, IHC | 5,111 | 13.4% | 5,959 |
| HER2 | NGS, PCR, PCR-based sequencing, FISH | 4,521 | 11.8% | 5,352 |
| MET exon 14 skipping | NGS | 5,111 | 13.4% | 5,959 |
| HER2 IHC | IHC | 7,291 | 19.1% | 8,216 |
| MET IHC or FISH | IHC, FISH | 8,783 | 23.0% | 10,052 |
| NGS (Overall) | NGS | 5,111 | 13.4% | 5,959 |
Testing coverage is calculated using the ROOT HEALTH NSCLC cohort as the denominator. Some patients may have undergone repeated testing or multiple testing modalities; therefore, the number of tests performed may exceed the number of patients tested.
Back to Data